TMS vs. Spravato: Which Is Right for You?
· Updated November 2026 · Aazaz Haq, MD
TMS and Spravato are the two treatments we provide most often at McLean NTC, and patients frequently ask which one they should start with. Both are good options with solid evidence. The choice usually comes down to speed, schedule and how you feel about a medicine versus a device.
The short answer
Both TMS and Spravato are well-studied, insurance-covered options for treatment-resistant depression. Spravato tends to work faster and involves fewer but longer visits, with a ride home required. TMS takes a few weeks, involves short daily visits, and lets you drive yourself. If one does not help enough, the other is often the next step.
The basics
- TMS uses magnetic pulses from a coil on the scalp to stimulate mood circuits. FDA-cleared for depression since 2008. No medicine is given.
- Spravato is esketamine, a nasal spray you take in our clinic under supervision. FDA-approved in 2019 for treatment-resistant depression, and since 2025 it can be used with or without a daily antidepressant.
Speed
Spravato usually works faster. Some people notice a change within days. TMS typically takes a few weeks, with many people improving in weeks three to six.
Effectiveness
Both help a meaningful share of people who did not improve with antidepressants. In everyday clinics, about 6 in 10 people respond to TMS. In a large 2023 trial, about 27% of people on Spravato were in remission at eight weeks, compared with about 18% on a standard add-on medication. Neither helps everyone, and there are no large trials comparing the two directly.
A treatment day
TMS: about 19 minutes for standard stimulation or about 3 minutes for theta burst, then you drive yourself back to work or home. Spravato: plan on 2 to 2.5 hours, including two hours of required monitoring. You need a ride, and you cannot drive until the next day after a full night's sleep.
Schedule
TMS is daily on weekdays for about six weeks, then a taper. Spravato is twice a week for four weeks, then weekly, then weekly or every other week for people who are doing well. Spravato involves fewer visits; TMS involves shorter ones.
Side effects
TMS: headache and scalp discomfort, mostly early; seizure is rare. Spravato: dissociation, sleepiness, nausea and a temporary rise in blood pressure, mostly during the two hours after a dose. Our guides on TMS safety and Spravato and ketamine safety give the numbers.
Insurance
Both are covered by most major plans, including Medicare, usually with prior authorization. Our insurance team handles the paperwork and tells you your expected cost before you start.
How I help people choose
I lean toward Spravato when faster relief is important or daily visits are not realistic. I lean toward TMS when someone wants to drive themselves, avoid a medicine, or has high blood pressure or a substance use history that makes Spravato less suitable. If one does not work well enough, the other is often the next step.
Our side-by-side comparison can help you prepare. To talk it through, request a consultation call.
Questions I hear often
If one does not work, will the other?
Possibly. They work through different mechanisms, so not responding to one does not predict not responding to the other. We often move from one to the other when the response is partial.
Which is better for older adults?
Both are used in older adults. TMS avoids medication interactions and blood pressure effects, which can be helpful in people with heart conditions. Spravato can be used with careful blood pressure monitoring. As a geriatric psychiatrist, I decide this one person at a time.
Which has fewer side effects?
TMS side effects are mild and local: headache and scalp discomfort. Spravato's side effects are stronger but short-lived, mostly within the two-hour monitoring period. Neither causes the weight gain or sexual side effects some antidepressants can.
What happens after the first phase
After a TMS course, we usually pause and check in at regular intervals, offering maintenance or a repeat course if symptoms return. After the first phase of Spravato, people who respond move to weekly or every-other-week maintenance, and we try to space treatments out as far as possible while keeping people well. Planning for the long term is part of the first conversation, not an afterthought.
References
- Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression (ESCAPE-TRD). N Engl J Med. 2023. PubMed
- Carpenter LL, et al. TMS for major depression: a multisite, naturalistic, observational study. Depress Anxiety. 2012. PubMed
- Popova V, et al. Esketamine nasal spray in treatment-resistant depression (TRANSFORM-2). Am J Psychiatry. 2019. PubMed